ArticleGastro hep advances2026
Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Semaglutide, a glucagon-like peptide-1 receptor agonist, is effective in the treatment of fibrotic (F2-F3) metabolic dysfunction-associated steatohepatitis (MASH) and has recently received accelerated Food and Drug Administration approval. However, the extent to which this new indication expands treatment eligibility beyond existing approvals for type 2 diabetes mellitus (T2DM) and obesity remains unclear. Methods: We analyzed 6936 community-dwelling adults from the National Health and Nutrition Examination Survey 2017 to 2020 cohort study after excluding individuals with viral hepatitis or excessive alcohol consumption. Semaglutide eligibility was defined according to Food and Drug Administration-approved indications for weight loss, high-risk T2DM, or fibrotic MASH. Findings were validated in the Mainz biopsy cohort (n = 213) with biopsy-proven metabolic dysfunction-associated steatotic liver disease and F2-F3 fibrosis. Results: In the US general population, 51.5% met indications for semaglutide therapy for weight loss or high-risk T2DM. Among individuals with metabolic dysfunction-associated steatotic liver disease, 80.9% qualified for treatment based on conventional indications, increasing to 95.4% in those with fibrotic MASH. Including fibrotic MASH as an additional indication raised the overall eligibility marginally from 51.5% to 51.8%. Aligning with these findings from the general population, we found that 80.3% of patients with biopsy proven F2-F3 fibrosis were eligible for semaglutide irrespective of fibrotic MASH. Conclusion: Semaglutide eligibility is high in the US general population and the new fibrotic MASH indication largely overlapped with pre-existing indications. The findings highlight the close overlap between metabolic comorbidities and liver disease and emphasize the need for an integrated, patient-centered approach to semaglutide, alongside policies that improve access and reimbursement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.